| Literature DB >> 35214164 |
Hellen Windolf1, Rebecca Chamberlain1, Arnaud Delmotte2, Julian Quodbach1,3.
Abstract
Falsified medicines are a major issue and a threat around the world. Various approaches are currently being investigated to mitigate the threat. In this study, a concept is tested that encodes binary digits (bits) on the surface of Fused Deposition Modelling (FDM) 3D printed geometries. All that is needed is a computer, a FDM 3D printer and a paper scanner for detection. For the experiments, eleven different formulations were tested, covering the most used polymers for 3D printing in pharma: Ethylene-vinyl acetate (EVA), polyvinyl alcohol (PVA), polylactic acid (PLA), Hypromellose (HPMC), ethyl cellulose (EC), basic butylated-methacrylate-copolymer (EPO), and ammonio-methacrylate-copolymer type A (ERL). In addition, the scanning process and printing process were evaluated. It was possible to print up to 32 bits per side on oblong shaped tablets corresponding to the dimensions of market preparations of oblong tablets and capsules. Not all polymers or polymer blends were suitable for this method. Only PVA, PLA, EC, EC+HPMC, and EPO allowed the detection of bits with the scanner. EVA and ERL had too much surface roughness, too low viscosity, and cooled down too slowly preventing the detection of bits. It was observed that the addition of a colorant or active pharmaceutical ingredient (API) could facilitate the detection process. Thus, the process could be transferred for 3D printed pharmaceuticals, but further improvement is necessary to increase robustness and allow use for more materials.Entities:
Keywords: FDM 3D printing; anti-counterfeiting; blind-watermarking; falsified medicine; personalized medicine; traceability
Year: 2022 PMID: 35214164 PMCID: PMC8879528 DOI: 10.3390/pharmaceutics14020432
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Composition of the filaments used.
| Filament | Materials | Concentration/% | Manufacturer/Source |
|---|---|---|---|
| PLA | Polylactic acid (PLA) | 100 | Bavaria filaments, Freilassing, Germany |
| PVA | Polyvinyl alcohol (PVA) | 100 | Parteck MXP®, Merck, Darmstadt, Germany |
| PVA + PZQ [ | Polyvinyl alcohol (PVA) | 95 | Parteck MXP®, Merck, Darmstadt, Germany |
| Praziquantel (PZQ) | 5 | Bayer AG, Leverkusen, Germany | |
| PVA + PDM [ | Polyvinyl alcohol (PVA) | 84 | Parteck MXP®, Merck, Darmstadt, Germany |
| Mannitol | 10 | Parteck M®, Merck, Darmstadt, Germany | |
| Pramipexole 2 HCl*H2O (PDM) | 5 | Chr. Olesen, Gentofte, Denmark | |
| Fumed silica | 1 | Aerosil® 200 VV Pharma, Evonik, Essen, Germany | |
| PVA + Triam [ | Triamcinolone acetonide (Triam) | 5 | Farmabios, Gropello Cairoli, Italy |
| Polyethylene glycol 300 | 10 | Polyglycol 300, Clariant, Pratteln, Switzerland | |
| Polyvinyl alcohol (PVA) | 85 | Parteck MXP®, Merck, Darmstadt, Germany | |
| PVA + colorant | Polyvinyl alcohol (PVA) | 84 | Parteck MXP®, Merck, Darmstadt, Germany |
| Mannitol | 10 | Parteck M®, Merck, Darmstadt, Germany | |
| Methylene blue | 5 | Spectrum Lab Products, Gardena, CA, US | |
| Fumed silica | 1 | Aerosil® 200 VV Pharma, Evonik, Essen, Germany | |
| EPO + API | Basic butylated-methacrylate- copolymer (EPO) | 80 | Eudragit E PO®, Evonik, Essen, Germany |
| Pramipexole 2 HCl*H2O (PDM) | 20 | Chr. Olesen, Gentofte, Denmark | |
| EC | Ethyl cellulose (EC) | 100 | Aqualon® N10, Ashland, KY, US |
| EC + HPMC [ | Ethyl cellulose (EC) | 72.93 | Aqualon® N10, Ashland, KY, US |
| Hypromellose (HPMC) | 16.67 | Metolose 60SH 50, Shin Etsu Chemical, Tokyo, Japan | |
| Triethyl citrate | 10 | Citrofol AI Extra, Jungbunzlauer, Basel, Switzerland | |
| Fumed silica | 0.4 | Aerosil® 200 VV Pharma, Evonik, Essen, Germany | |
| EVA + PVA | Ethylene-vinyl acetate copolymer 82:18 (EVA) | 25 | Escorene® FL01418, TER Chemicals, Hamburg, Germany |
| Polyvinyl alcohol (PVA) | 65 | Parteck MXP®, Merck, Darmstadt, Germany | |
| Mannitol | 10 | Parteck M®, Merck, Darmstadt, Germany | |
| EVA + PVP-VA + API | Ethylene-vinyl acetate copolymer 82:18 (EVA) | 35 | Escorene® FL01418, TER Chemicals, Hamburg, Germany |
| Vinylpyrrolidone-vinyl acetate copolymer 60:40 | 15 | Kollidon VA 64®, BASF, Ludwigshafen a. R., Germany | |
| Levodopa | 40 | Zhejiang Wild Wind Pharmaceutical, Dongyang, China | |
| Benserazide | 10 | BioPharma Synergies, Barcelona, Spain | |
| ERL + API [ | Anhydrous Theophylline | 30 | BASF, Ludwigshafen a. R., Germany |
| Ammonio-methacrylate-copolymer type A (ERL) | 62.6 | Eudragit® RL PO, Evonik, Essen, Germany | |
| Stearic acid | 7 | Baerlocher, Lingen, Germany | |
| Fumed silica | 0.4 | Aerosil® 200 VV Pharma, Evonik, Essen, Germany |
Figure 1Detail from the watermark-embedding process. The side length (green + red) is recognized without the roundings and is encoded with bits.
Figure 2Scheme of the watermark embedding parameters and procedure. Adapted from the illustration in the original publication [53], IEEE, 2020.
Settings of the 3D printing process.
| Filament | Bed Temperature/°C | Nozzle Temperature/°C |
|---|---|---|
| PLA | 60 | 215 |
| PVA | 90 | 190 |
| PVA + PZQ | 90 | 188 |
| PVA + PDM/colorant | 60 | 188 |
| PVA + Triam | 60 | 190 |
| EPO + API | 45 | 176 |
| ERL + API | 55 | 180 |
| EC | 60 | 180 |
| EC + HPMC | 63 | 180 |
| EVA + PVA | 50 | 220 |
| EVA + PVP-VA + API | 50 | 220 |
Settings of the scanning process.
| Filament | Brightness | Contrast |
|---|---|---|
| PLA | −19 | 31 |
| PVA | −100 | 30 |
| PVA + PZQ | −100 | 55 |
| PVA + PDM | −19 | 70 |
| PVA + colorant | −50 | 25 |
| PVA + Triam | −100 | 50 |
| EPO + API | −100 | 60 |
| ERL + API | −100 | 40 |
| EC | −45 | 40 |
| EC + HPMC | −80 | 55 |
| EVA + PVA | −70 | 40 |
| EVA + PVP-VA + API | −70 | 40 |
Figure 3Example of the detection process (EC + HPMC); form left to right: scanned 3D printed oblong tablet with region of interest, detected watermark-patch and result of the bit detection.
Minimum bit insertion per side (parity bits marked in grey).
| 0 | 1 | 1 |
| 1 | 1 | 0 |
| 1 | 0 | 1 |
Figure 4Pictured G-Code (left) and scanning image of 3D printed oblong tablet with 4 bits + 5 parity bits per side (right). Oblong tablet size: 12 mm length, 4 mm height, 4 mm width.
Figure 5Pictured G-Code (left) and scanning image of 3D printed oblong tablet with 32 bits + 13 parity bits per side. Oblong tablet size: 23 mm length, 6 mm height, 8 mm width.
Maximum bit code: 9 bits per line, 5 bits in height. 8 × 4 bits with 13 parity bits (grey marked).
| 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 |
| 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
Figure 6G-Codes (top) and scanning images of 3D printed oblong tablets (bottom). Left: 0.2 mm layer height (9 bits), right: 0.1 mm layer height (18 bits).
Figure 7Top: results of the detection process of printed tablet with 0.2 mm layer height (9 bits). Bottom: Results of the detection process of printed tablet with 0.1 mm layer height (18 bits).
Figure 8Influence of the orientation of the tablet with bits to the scan light. Left: perpendicular to the scan light, right: parallel to the scan light. Tablet: PLA with 25 bits.
Bit code: 5 bits per line, 5 bits in height. 4 × 4 bits with 9 parity bits (grey marked).
| 1 | 1 | 0 | 0 | 0 |
| 0 | 1 | 1 | 0 | 0 |
| 1 | 1 | 0 | 1 | 1 |
| 1 | 1 | 0 | 0 | 0 |
| 1 | 0 | 1 | 1 | 1 |
Material variations: images, scans and detection result.
| Filament | Image | Scan (Parallel Orientation) | Detection | |
|---|---|---|---|---|
| PLA |
|
| Yes | (a) |
| PVA |
|
| No | (b) |
| PVA + PZQ |
|
| No | (c) |
| PVA + PDM |
|
| No | (d) |
| PVA + |
|
| Yes | (e) |
| PVA + Triam |
|
| Yes | (f) |
| EPO + API |
|
| Yes | (g) |
| EC |
|
| Yes | (h) |
| EC + HPMC |
|
| Yes | (i) |
| EVA + PVA |
|
| No | (j) |
| EVA + PVP -VA + API |
|
| No | (k) |
| ERL + API |
|
| No | (l) |
Figure 9Filament PVA + PZQ printed at 188 °C (a) and 190 °C (c). Filament EPO + API printed at 176 °C (b) and 185 °C (d). Scanning image (e) present the scan of printed tablet shown in (c), and scanning image (f) present the scan of printed tablet shown in image (d).
Melt viscosity of the used materials at their specific print temperatures.
| Filament | Nozzle Temperature/°C | Melt Viscosity/kPa*s |
|---|---|---|
| PVA | 190 | 7.251 |
| PVA + PZQ/PDM/colorant | 188 | 6.407 |
| PVA + Triam | 190 | 4.321 |
| EPO + API | 176 | 0.169 |
| EC | 180 | 24.200 |
| EC + HPMC | 180 | 15.920 |
| EVA + PVA | 220 | 0.251 |
| EVA + PVP-VA + API | 220 | 0.135 |
Overview of detection influences and results.
| Filament | Transparent/ | Surface Roughness | Visible to the Eye | Detectable | Likely Reason |
|---|---|---|---|---|---|
| PLA | no | no | yes | yes | Good solidification behavior, |
| PVA | yes | no | yes | no | Transparent, reflection of the scan-light. High melt viscosity. |
| PVA + API | no | yes | Transparent, | ||
| PVA + | no | no | yes | yes | The colorant decreases the transparency of PVA. High melt viscosity. |
| EPO + API | no | no | yes | yes | Good solidification behaviour, low melt viscosity, |
| ERL + API | no | yes | no | no | Too rough, no bits recognizable. |
| EC | no | no | yes | yes | Good solidification behaviour, high melt viscosity, |
| EC + HPMC | no | no | yes | yes | Good solidification behaviour, high melt viscosity, |
| EVA + PVA | no | no | no | no | Solidification of the printed object occurs too slowly + low melt viscosity, the bits and layers deform. |
| EVA + PVP-VA + API | no | yes | no | no | Solidification of the printed object occurs too slowly + low melt viscosity, the bits and layers deform. |